Search clinical trials for: D2

Total 1023 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Dose Proportionality of Extended Release Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients

Schizophrenia | Insomnia
Emory University
National Institute on Drug Abuse (NIDA)

Recruiting

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 (VNS in OUD UH3)

Opioid Use Disorder | Opioid Use | Withdrawal Symptoms

United States
Maosheng Fang

Unknown

The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia

Schizophrenia
Janssen Research & Development, LLC

Completed

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Psychotic Disorders | Schizophrenia | Schizophrenic Disorders | Dementia Praecox

United States, Belgium, Poland, Bulgaria, India, Romania, Russian Federation, Ukraine, Korea, Republic of, Estonia, Finland
National Taiwan University Hospital

Unknown

A Pharmacokinetic Study of Paliperidone ER

Schizophrenia | Schizoaffective Disorder

Taiwan
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Schizoaffective Disorder

United States, Ukraine, Bulgaria, India, Malaysia, Romania, South Africa, Philippines
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

Schizophrenia

United States, Taiwan, India
Janssen Pharmaceutica

Completed

Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Schizophrenia
Janssen-Cilag B.V.

Completed

INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

Schizophrenia

Netherlands
Johnson & Johnson Taiwan Ltd

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Schizophrenia
Xian-Janssen Pharmaceutical Ltd.

Completed

A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia

Schizophrenia
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia (PERTAIN)

Schizophrenia

Poland, Israel, Romania, Germany, Lithuania, Croatia, France
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder
Janssen-Cilag, S.A.

Completed

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia (PERFLEX)

Schizophrenia

Colombia, Argentina
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder

Mood Disorders | Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Bioequivalence Study of 15 mg ER OROS Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

Schizophrenia
Mahidol University
Siriraj Hospital

Completed

Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin

Cancer

Thailand
University of Alberta
Natural Sciences and Engineering Research Council, Canada

Active, not recruiting

The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise

Health

Canada
Luye Pharma Group Ltd.
Alliance for Clinical Trials in Oncology; Evolution Research Group

Completed

Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients

Schizophrenia Patients

United States
Seoul National University Hospital

Completed

The Effect of Paliperidone Palmitate in Schizophrenia (sustenna)

Schizophrenia

Korea, Republic of
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

Schizophrenia

Brazil
Ortho-McNeil Janssen Scientific Affairs, LLC

Terminated

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Schizophrenia

United States, China, Colombia, Bulgaria, India, Malaysia, Russian Federation, Ukraine, Canada, Korea, Republic of, Brazil, Czech Republic
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia

Schizophrenia
University of California, Irvine
Janssen, LP

Unknown

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

Schizophrenia

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone

Schizophrenia
Turku University Hospital

Active, not recruiting

Neuromolecular Risk Factors for Obesity (PROSPECT)

Obesity

Finland
Boehringer Ingelheim

Completed

Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers

Healthy
Fudan University

Recruiting

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (Miracle-G)

Adenocarcinoma | Metastatic Cancer | Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Oligometastatic Disease | Stomach Neoplasm | Adenocarcinoma of the Stomach | Gastroesophageal-junction Cancer | Metastatic Adenocarcinoma

China
Montefiore Medical Center
Albert Einstein College of Medicine

Completed

Prochlorperazine vs Metoclopramide

Migraine

United States
Xijing Hospital
Xi'an Central Hospital; First Affiliated Hospital Xi'an Jiaotong University; Tang-Du... and other collaborators

Terminated

Optimizing Early Enteral Nutrition in Severe Stroke (OPENS)

Dysphagia | Acute Stroke | Severe Stroke

China
Janssen Korea, Ltd., Korea

Completed

A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate

Schizophrenia

Korea, Republic of
Ain Shams University
Future University in Egypt

Completed

The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients

Enteral Feeding Intolerance

Egypt
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Pharmacokinetics Of Celecoxib Test Formulations

Healthy Volunteers

United States
University of Malaya

Completed

Role of Prophylactic Metoclopramide With Tramadol in Trauma Patients

Trauma | Opioid Analgesic Adverse Reaction

Malaysia
Xian-Janssen Pharmaceutical Ltd.

Completed

A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia

Schizophrenia

China
Janssen-Cilag Ltd.,Thailand

Completed

Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants (PRESENT)

Schizophrenia

Thailand
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

Schizophrenia
Indiana University School of Medicine
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Study of Paliperidone ER in Adolescents and Young Adults With Autism

Autism

United States

3

Subscribe